BRPI0415744A - lipìdios contendo ácidos graxos Èmega-3 e Èmega-6 - Google Patents

lipìdios contendo ácidos graxos Èmega-3 e Èmega-6

Info

Publication number
BRPI0415744A
BRPI0415744A BRPI0415744-3A BRPI0415744A BRPI0415744A BR PI0415744 A BRPI0415744 A BR PI0415744A BR PI0415744 A BRPI0415744 A BR PI0415744A BR PI0415744 A BRPI0415744 A BR PI0415744A
Authority
BR
Brazil
Prior art keywords
omega
pufa
fatty acids
lipids containing
glycerophospholipid
Prior art date
Application number
BRPI0415744-3A
Other languages
English (en)
Inventor
Gai Ben Dror
Dorit Platt
Orly Farkash
Rassan Zuabi
Zohar Bar-On
Avidor Shulman
Dori Pelled
Original Assignee
Enzymotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzymotec Ltd filed Critical Enzymotec Ltd
Publication of BRPI0415744A publication Critical patent/BRPI0415744A/pt
Publication of BRPI0415744B1 publication Critical patent/BRPI0415744B1/pt
Publication of BRPI0415744B8 publication Critical patent/BRPI0415744B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

"LIPìDIOS CONTENDO áCIDOS GRAXOS ÈMEGA-3 E ÈMEGA-6". Apresenta-se uma preparação lipídica compreendendo um glicerofosfolipídio ou seu sal, conjugado ou derivado, particularmente fosfaditilserina (PS), fosfatidilcolina (PC), fosfatidiletanolamina (PE), fosfatidilinositol (PI), fosfatidilglicerol (PG) e ácido fosfatídico (PA) e grupos acila de ácido graxo poliinsaturado (PUFA), particularmente grupos acila de ácido graxo poliinsaturado de cadeia longa (LC-PUFA), como grupos acila ómega-3 e/ou ómega-6, em que o dito PUFA está covalentemente ligado ao dito glicerofosfolipídio. As preparações apresentadas possuem uma melhor bioatividade e são utilizáveis no tratamento de vários estados e distúrbios cognitivos e mentais e para a manutenção das funções normais de sistemas e processos relacionados ao cérebro.
BRPI0415744A 2003-10-22 2004-10-21 uso de uma preparação lipídica contendo ácidos graxos ômega-3 e ômega-6, esta preparação, uso de glicerofosfolipídios, composição nutracêutica e artigo alimentar funcional BRPI0415744B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL15855203A IL158552A0 (en) 2003-10-22 2003-10-22 Lipids containing omega-3 fatty acids
IL158552 2003-10-22
PCT/IL2004/000957 WO2005037848A2 (en) 2003-10-22 2004-10-21 Glycerophospholipids containing omega-3 and omega-6 fatty acids

Publications (3)

Publication Number Publication Date
BRPI0415744A true BRPI0415744A (pt) 2006-12-19
BRPI0415744B1 BRPI0415744B1 (pt) 2018-07-17
BRPI0415744B8 BRPI0415744B8 (pt) 2021-05-25

Family

ID=34044222

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415744A BRPI0415744B8 (pt) 2003-10-22 2004-10-21 uso de uma preparação lipídica contendo ácidos graxos ômega-3 e ômega-6, esta preparação, uso de glicerofosfolipídios, composição nutracêutica e artigo alimentar funcional

Country Status (10)

Country Link
EP (2) EP1689413A2 (pt)
JP (2) JP2007509131A (pt)
KR (2) KR101331658B1 (pt)
CN (2) CN103381172A (pt)
AU (1) AU2004282006C1 (pt)
BR (1) BRPI0415744B8 (pt)
CA (1) CA2542504C (pt)
IL (3) IL158552A0 (pt)
RU (1) RU2362566C2 (pt)
WO (1) WO2005037848A2 (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
IL158553A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Method for preparing phosphatidylserine containing omega-3 acid moieties
US7935365B2 (en) * 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
IL158552A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Lipids containing omega-3 fatty acids
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5697293B2 (ja) * 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
BRPI0708365A2 (pt) * 2006-02-28 2011-04-26 Bristol - Myers Squibb Company uso de dha e ara na preparação de uma composição para regular expressão de gene
JP2008260743A (ja) * 2006-08-03 2008-10-30 Nagase Chemtex Corp Ｎｑｏ１発現増強剤
KR101881982B1 (ko) 2006-12-28 2018-07-25 산토리 홀딩스 가부시키가이샤 신경 재생제
EP2144618B2 (en) 2007-03-28 2024-11-20 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
KR20150126977A (ko) * 2007-11-01 2015-11-13 엔지모테크 리미티드 유아 영양을 위한 지질 혼합물
US9085527B2 (en) 2008-07-08 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
US20130295171A1 (en) 2009-07-23 2013-11-07 U.S NUTRACEUTICALS, LLC d/b/a Valensa International Krill oil and reacted astaxanthin composition and associated method
TWI573591B (zh) 2009-10-29 2017-03-11 阿卡斯提製藥公司 經濃縮治療性磷脂質組合物
DK2493296T3 (en) 2009-10-30 2019-04-15 Retrotope Inc REMOVAL OF OXIDATIVE STRESS STATES WITH PUFA DERIVATIVES
EP2534488B1 (en) * 2010-02-11 2014-10-01 Katholieke Universiteit Leuven Phospholipid profiling of cancer
US8663704B2 (en) 2010-04-30 2014-03-04 U.S. Nutraceuticals, LLC Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans
WO2011137160A2 (en) * 2010-04-30 2011-11-03 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans
US9763897B2 (en) 2010-04-30 2017-09-19 U.S. Nutraceuticals, LLC Therapeutic astaxanthin and phospholipid composition and associated method
RU2467334C2 (ru) * 2010-08-24 2012-11-20 Федеральное государственное бюджетное учреждение "Дальневосточный научный центр физиологии и патологии дыхания" Сибирского отделения РАМН СПОСОБ ОЦЕНКИ МИКРОВЯЗКОСТИ МЕМБРАН ЭРИТРОЦИТОВ ПУТЕМ ВЫЧИСЛЕНИЯ КОЭФФИЦИЕНТА ЭКСИМЕРИЗАЦИИ ПИРЕНА Кэкс У БЕРЕМЕННЫХ, ПЕРЕНЕСШИХ ОБОСТРЕНИЕ ГЕРПЕС-ВИРУСНОЙ ИНФЕКЦИИ В ТРЕТЬЕМ ТРИМЕСТРЕ ГЕСТАЦИИ, С УЧЕТОМ ОПРЕДЕЛЕНИЯ ПРОЦЕНТНОГО СОДЕРЖАНИЯ ОЛЕИНОВОЙ КИСЛОТЫ В МЕМБРАНАХ ЭРИТРОЦИТОВ
GB201016139D0 (en) * 2010-09-24 2010-11-10 Univ Leuven Kath Cancer phosholipidome
KR102110175B1 (ko) 2011-04-26 2020-05-13 레트로토프 인코포레이티드 Ｐｕｆａ 산화와 관련된 장애
KR102020611B1 (ko) 2011-04-26 2019-09-10 레트로토프 인코포레이티드 Ｐｕｆａ와 관련된 신경퇴행성 질환 및 근육 질환
WO2012148930A2 (en) 2011-04-26 2012-11-01 Retrotope, Inc. Oxidative retinal diseases
EP2701696B1 (en) 2011-04-26 2020-06-03 Retrotope, Inc. Impaired energy processing disorders and mitochondrial deficiency
US8846604B2 (en) 2011-09-02 2014-09-30 Artic Nutrition AS Lipid compositions with high DHA content
IN2014DN08089A (pt) 2012-02-29 2015-05-01 Braun Melsungen Ag
US20150044138A1 (en) * 2012-03-02 2015-02-12 N.V. Nutricia Method for improving functional synaptic connectivity
US20150030718A1 (en) 2012-03-12 2015-01-29 Aker Biomarine Antarctic As Oxidixable fatty acid composition delivery form
WO2014045127A2 (en) 2012-09-19 2014-03-27 Aker Biomarine As Omega-3 phospholipid supplements for females
AU2014229540A1 (en) 2013-03-14 2015-10-08 Aker Biomarine Antarctic As Omega- 3 phospholipid supplements for improved brain maturity
CN103242407A (zh) * 2013-05-15 2013-08-14 张雅茹 含多不饱和脂肪酰基的磷脂酰甾醇和/或磷脂酰甾烷醇及制备方法和应用
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
CN103609752B (zh) * 2013-12-02 2016-05-25 内蒙古伊利实业集团股份有限公司 一种改善脑部认知功能的组合物及其制备方法与应用
JP6291058B2 (ja) * 2013-12-05 2018-03-14 エンザイモテック リミティド セリングリセロリン脂質調製物及び発作の治療方法
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
US10898525B2 (en) 2014-04-30 2021-01-26 Aker Biomarine Antarctic As Krill oil preparations and their uses
AU2015348010B2 (en) * 2014-11-20 2020-02-27 Frutarom Limited Phospholipid preparations for the improvement of communication skills
AU2016217559A1 (en) 2015-02-11 2017-08-31 Aker Biomarine Antarctic As Lipid extraction processes
NZ735362A (en) 2015-02-11 2019-01-25 Aker Biomarine Antarctic As Lipid compositions
US10894056B2 (en) * 2015-07-13 2021-01-19 Enzymotec Ltd Phospholipid preparations for the improvement of sleep
AU2016361227B2 (en) 2015-11-23 2021-06-10 Biojiva Llc Site-specific isotopic labeling of 1, 4-diene systems
KR101744203B1 (ko) * 2016-01-12 2017-06-20 (주)노터스생명과학 포스파티딜콜린을 유효성분으로 포함하는 신장질환 예방 또는 치료용 약학 조성물
WO2017153841A1 (en) 2016-03-10 2017-09-14 Enzymotec Ltd. Phospholipid preparations for the improvement of brain plasticity
ES2663392B2 (es) * 2016-05-17 2018-09-24 Universidad De La Laguna Complemento nutricional para la protección de neuronas frente al riesgo de Alzheimer y Parkinson en mujeres combinando isoflavonas y ácido docosahexaenoico.
EP3811938A1 (en) 2016-09-29 2021-04-28 Société des Produits Nestlé S.A. Omega-3 fatty acid and choline in compositions and methods that attenuate cognitive aging in individuals who do not have dementia
CN109793802A (zh) * 2017-11-16 2019-05-24 西双版纳华坤生物科技有限责任公司 一种用于预防和治疗帕金森症的物质及制备方法和用途
US20210069146A1 (en) * 2018-01-31 2021-03-11 Kinjirushi Co., Ltd. Recognition ability improving agent
WO2019156210A1 (ja) 2018-02-09 2019-08-15 日本水産株式会社 リンパ循環改善剤
CN108721269A (zh) * 2018-07-10 2018-11-02 广东海洋大学 一种epa与dha混合剂在防治焦虑和快感缺乏方面的应用
IL321252A (en) 2020-02-21 2025-08-01 Retrotope Inc Processes for isotopic alteration of polyunsaturated fatty acids and their derivatives
JP7539076B2 (ja) * 2020-02-29 2024-08-23 国立大学法人九州大学 α－グルコシダーゼ阻害剤
JPWO2022050355A1 (pt) * 2020-09-04 2022-03-10
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
CN113749255B (zh) * 2021-09-15 2022-11-29 江南大学 一种磷脂组合物在修复肌肉损伤的应用
GR20220100576A (el) * 2022-07-13 2024-02-09 Σταυρουλα Κωνσταντινου Μπασακιδου Βρωσιμα ελαια εμπλουτισμενα με θρεπτικα συστατικα για την ενισχυση της λειτουργιας του εγκεφαλου

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54117034A (en) * 1978-02-28 1979-09-11 Nippon Shoji Kk Treating agent for consciousness and perception motion disorder
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
JPH0279311A (ja) * 1988-09-14 1990-03-19 Ngk Insulators Ltd 電気設備の高電圧瑞末部における接地層先端部の電界緩和構造及びその形成方法
JPH03188088A (ja) * 1989-12-15 1991-08-16 Ajinomoto Co Inc 新規リゾホスファチジルセリン
JPH0717855A (ja) * 1992-09-02 1995-01-20 Maruha Corp 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
GB9301629D0 (en) * 1993-01-27 1993-03-17 Scotia Holdings Plc Formulations containing unsaturated fatty acids
JP3467794B2 (ja) * 1993-03-09 2003-11-17 日本油脂株式会社 学習能向上剤
JPH06279311A (ja) * 1993-03-26 1994-10-04 Sagami Chem Res Center プロテインキナーゼｃアイソザイムの活性化剤
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
US5716614A (en) * 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
WO1997039759A2 (en) * 1996-04-24 1997-10-30 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
US6344482B1 (en) * 1997-04-23 2002-02-05 Andrew L. Stoll Omega-3 fatty acids in the treatment of bipolar disorder
FR2762993B1 (fr) * 1997-05-06 1999-08-13 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
WO2000007577A2 (de) * 1998-08-06 2000-02-17 Wolfgang Stremmel Phosphatidylcholin als arzneimittel mit schleimhautschützender wirkung
US20040213766A1 (en) * 2002-11-27 2004-10-28 Cedric Francois Compositions and methods for treating transplants
IL158552A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Lipids containing omega-3 fatty acids

Also Published As

Publication number Publication date
BRPI0415744B1 (pt) 2018-07-17
IL174925A0 (en) 2008-02-09
EP2258377B1 (en) 2019-08-28
RU2006116267A (ru) 2007-12-10
BRPI0415744B8 (pt) 2021-05-25
EP2258377A3 (en) 2011-10-05
KR20120115419A (ko) 2012-10-17
IL224977A (en) 2014-09-30
IL174925A (en) 2014-01-30
WO2005037848A2 (en) 2005-04-28
CA2542504C (en) 2014-01-07
JP5835671B2 (ja) 2015-12-24
IL158552A0 (en) 2004-05-12
JP2007509131A (ja) 2007-04-12
EP2258377A2 (en) 2010-12-08
AU2004282006A1 (en) 2005-04-28
KR20060094526A (ko) 2006-08-29
CN103381172A (zh) 2013-11-06
AU2004282006C1 (en) 2010-10-21
RU2362566C2 (ru) 2009-07-27
KR101331658B1 (ko) 2013-11-20
EP1689413A2 (en) 2006-08-16
WO2005037848A3 (en) 2005-05-26
CN1897955A (zh) 2007-01-17
JP2012211168A (ja) 2012-11-01
AU2004282006B2 (en) 2010-04-15
CA2542504A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
BRPI0415744A (pt) lipìdios contendo ácidos graxos Èmega-3 e Èmega-6
Yalagala et al. Dietary lysophosphatidylcholine-EPA enriches both EPA and DHA in the brain: potential treatment for depression
DE60330154D1 (de) Resolvine: biotemplate zur durchführung therapeutischer anwendungen
Martins de Lima et al. Mechanisms by which fatty acids regulate leucocyte function
WO2005089744A3 (en) Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
DE60132081D1 (de) ZUBEREITUNG ZUR VORBEUGUNG UND BEHANDLUNG VON GEFÄßKRANKHEITEN
CA2838312C (en) Therapeutic application of parenteral krill oil
CA2128706A1 (en) Polyunsaturated fatty acid based drugs, in particular docosahexaenoic acid, as platelet aggregation inhibitors and against essential fatty acid deficiencies of the brain
AU2003217759A1 (en) Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression
Sehl et al. In vitro lipolysis and lymphatic absorption of n-3 long-chain PUFA in the rat: influence of the molecular lipid species as carrier
De Koning Phospholipids of marine origin—the squid (Loligo vulgaris)
Hiratsuka et al. Effect of dietary docosahexaenoic acid connecting phospholipids on the lipid peroxidation of the brain in mice
US20110274746A1 (en) Therapeutic Liposomes and Methods For Producing and Using the Same
Tsushima et al. Lysophosphatidylserine form DHA maybe the most effective as substrate for brain DHA accretion
US20070009590A1 (en) Physiologically active composition based on phosphatidylserine
Amara et al. In vitro gastrointestinal digestion of marine oil emulsions and liposomal solutions: Fate of LC-PUFAs upon lipolysis
Chaudière et al. Unaltered brain membranes after prolonged intake of highly oxidizable long-chain fatty acids of the (n− 3) series
Chen et al. Preparation of n‐3 Polyunsaturated Phosphatidylglycerol from Salmon Roe Lipids by Phospholipase D and In Vitro Digestion
JPH09110888A (ja) リン脂質組成物
EP1909800B1 (de) Acylglycerophospholipide zur behandlung von krebs-begleiterscheinungen
Swartz et al. Acyl transfer reactions of retina
CO6230993A2 (es) Uso de una sal de cobre enmascarada o recubierta para el tratamiento de degeneracion macular
Meskini Phospholipase D as a potential target for the antiproliferative effects of polyunsaturated fatty acids in rat thymocytes
TERAO Factors affecting the oxidative stability of emulsified oil and membranous phospholipids
Sul Lipid composition and physiological studies on the marine ciliated protozoan Parauronema acutum.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/10/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2854 DE 16-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.